Vir Biotechnology launches public stock offering following ECLIPSE 1 Phase 3 results
Vir filed a preliminary prospectus supplement on November 12, 2026 to sell common stock, as the company advances its hepatitis delta and oncology pipelines.
SEC filing (3)